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Statins and Risk of Cancer
A Retrospective Cohort Analysis of 45,857 Matched Pairs From an
Electronic Medical Records Database of 11 Million Adult Americans
Claudio Marelli, MD,* Candace Gunnarsson, EDD,* Susan Ross, MD,* Sara Haas, MS,*
Donna F. Stroup, PHD, MSC,* Paul Cload, PHD,† Paul Clopton, MS,‡ Anthony N. DeMaria, MD§
Cincinnati, Ohio; Chalfont St Giles, Bucks, United Kingdom; and San Diego, California
Objectives The purpose of this study was to determine whether cancer can be attributed to statin use among a general pop-
ulation of older adults in the United States with at least 3 years of follow-up.
Background Statins are widely prescribed drugs in the United States for the management of dyslipidemia, atherosclerosis,
and cardiovascular event risk reduction. Unsettled scientific debate about the association of statins with cancer
continues, with high-profile studies showing conflicting results.
Methods A retrospective cohort analysis of the incidence of cancer in older adults who have and who have not used st-
atins was performed. More than 11 million analyzable patient records from January 1990 through February
2009 were drawn from the General Electric Centricity electronic medical records database. Propensity matching
found pairs of patients receiving and not receiving statin therapy who shared similar propensities for statin use.
Results Propensity score methods matched 45,857 comparison pairs of patients taking a statin and patients not taking
a statin. The average time in the database was 8 years, with pairs being followed for an average of 4.6 and 4.7
years. After matching, the incidence of cancer in patients taking a statin was 11.37% compared with 11.11% in
matched patients not taking a statin. Multivariate-matched Cox regression analysis showed a nonsignificant haz-
ard ratio of 1.04 (95% confidence interval: 0.99 to 1.09). Kaplan-Meier curves for diagnosis of any cancer up to
10 years also showed no difference for patients taking a statin and those not taking a statin.
Conclusions This retrospective analysis of nearly 46,000 propensity-matched pairs demonstrated no statistically significant
increased risk of cancer associated with statins. (J Am Coll Cardiol 2011;58:530–7) © 2011 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2011.04.015Statins (or 3-hydroxy-3-methylglutaryl coenzyme A reduc-
tase inhibitors) are among the most prescribed drugs in the
United States for the management of dyslipidemia, athero-
sclerosis, and cardiovascular event risk reduction. Recent
published results of the JUPITER (Justification for the Use
of Statins in Primary Prevention: An Intervention Trial
Evaluating Rosuvastatin) (1) has further fueled the debate
about the value of expanding indications for statin therapy
to lower risk individuals to reduce their relative risk of
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ccepted April 7, 2011.cardiovascular disease (2). Available analyses (3,4) assume
that statin therapy is well tolerated and safe, even with
long-term use, but the evidence acquired so far is limited by
several factors: the number and characteristics of the sub-
jects studied, relatively short follow-up period, and con-
straints of patient selection and rigid treatment protocols
typical of randomized, controlled trials.
For more than a decade, the scientific debate about the
association of statins with cancer has been unsettled (5–18).
Recently, this debate was rekindled with the high-profile
publication of 2 studies of a new lipid-lowering agent,
ezetimibe, in combination with a statin. The first study, the
SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) trial
(19), a randomized, placebo-controlled study of safety in
1,873 patients with a median follow-up of 52.2 months,
reported that cancer occurred significantly more frequently
in the treatment group (relative risk 95% confidence interval
[CI]: 1.13 to 2.12). The other study (20), a hypothesis-
testing meta-analysis of cancer data from more than 20,617
patients in 2 large ongoing trials of the same regimen: SHARP
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(Improved Reduction of Outcomes: Vytorin Efficacy Interna-
tional Trial), came to the opposite conclusion, namely, that
these trials do not provide evidence of an association between
lipid-lowering drugs and cancer. Meta-analyses of the 2 on-
going trials yielded a risk ratio of 0.96 (95% CI: 0.82 to 1.12),
and of all 3 of the aforementioned trials, a risk ratio of 1.06
(95% CI: 0.92 to 1.22). It is extremely important to answer
this question unambiguously because statins (with or with-
out ezetimibe) are widely prescribed throughout the world.
More definitive studies, particularly real-world observa-
tional studies involving more patient data with longer
follow-up, are clearly needed.
Toward this end, we performed a retrospective cohort
analysis of the incidence of cancer in older adults according
to their use of statins. Analyzable patient records were
drawn from the General Electric (GE) Centricity database,
a large commercial electronic medical records (EMR) sys-
tem, used by more than 20,000 clinicians for the manage-
ment of medical records of more than 30 million patients
throughout the United States (21). This nationally repre-
sentative database of anonymized longitudinal medical re-
cords contains many clinical and demographic variables and
allows patients’ clinical conditions to be tracked over time.
Propensity score methods were used to develop matched
comparison groups of patients taking a statin and those not
taking a statin. This report presents our findings regarding
the incidence of cancer in these matched groups.
Methods
The primary objective of the study was to determine
whether cancer can be attributed to the use of statins among
a general population of older U.S. adults with at least 3 years
of follow-up.
Study design and patients. We analyzed records from the
GE Centricity EMR database. The a priori protocol and
statistical analysis plan were reviewed by a central institu-
tional review board, and an informed consent exemption
was obtained. Patient records had to contain a valid patient
age and documented activity dates between January 1, 1990,
and February 28, 2009, to be included in the analyzable
dataset.
For patients in the database up to February 2009, it was
determined whether they had ever received statin therapy.
Time zero was defined as the point at which patients began
to take statins or, if never on statins, the date of the first
recorded low-density lipoprotein (LDL) or total cholesterol
level in the database.
For those with sufficient medication history, men 45 years
of age and older and women 55 years of age and older at
time zero were selected, with the age cutoff based on the
SHAPE (Screening for Heart Attack Prevention and Ed-
ucation) Task Force report (22). Patients were excluded if
they had insufficient history in the database, defined for
statin users as 1 year before the start of medication or 2years after the start date and for
those not taking a statin, 3
years of history in the database,
younger than the age cutoffs at
the start of medication or at time
zero, and any patients with a
diagnosis of cancer before medi-
cation or time zero. The remain-
ing patients were treated as a
cohort for analysis.
Outcomes. The primary out-
come was diagnosis of any type of cancer recorded in the
medical record after time zero.
Calculation of propensity scores. Propensity scores for
receipt of statins were calculated for each of the patients
included in the analysis based on a nonparsimonious mul-
tivariable logistic regression model (23). Due to the poor
reporting of body mass index (BMI) and very low density
lipoprotein (VLDL), we imputed values for these measure-
ments before time zero based on age- and sex-specific
means. There were matches on 35 characteristics (see
Online Table 1 for complete listings of all variables).
Characteristics hypothesized to be associated with statin
use included smoking status, age, time in the database,
calendar time, sex, race, concomitant diagnoses, medica-
tions taken before time zero or statin initiation, total
cholesterol, VLDL, low-density lipoprotein (LDL), trig-
lycerides, the number of office visits before time zero or
statin initiation, record of Pap or prostate-specific anti-
gen test, and BMI.
Propensity score matching. The goal of the propensity
matching was to find pairs of patients taking and not taking
a statin who shared similar propensities for statin use based
on the matching variables. A SAS version 9.1 (SAS Insti-
tute, Cary, North Carolina) macro was created to use
nearest-neighbor matching on the estimated propensity
scores to choose matches for the statin patients (24). We
randomly ordered patients taking and those not taking a
statin and then chose the patients not taking a statin with
the propensity score closest to the first patient taking a
statin. We matched the propensity scores to 3 decimal
places. Both patients were then removed from the pool of
patients available for matching. This procedure was re-
peated for each patient taking a statin (25). We chose a
stringent (conservative) stopping rule to control as much as
possible for confounding in these observational data.
Assessment of residual bias. Differences in the distribu-
tion of patient characteristics were assessed before and after
matching. We used independent-sample tests for the de-
scriptive statistics before matching and paired-sample tests
after matching.
Statistical analysis. To assess the extent to which propen-
sity matching reduced confounders, the distribution of
several variables were compared before and after matching,
Abbreviations
and Acronyms
CI  confidence interval
EMR  electronic medical
records
LDL  low-density
lipoprotein
VLDL  very low density
lipoproteintaking into consideration sex, age, race, smoking status,
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screenings (Pap or prostate-specific antigen test), concom-
itant medications, and calendar time. Unmatched group
comparisons were made using t tests for independent
samples and chi-square tests. Matched group comparisons
were made using paired t tests and McNemar tests. Con-
ditional Cox regression was used to account for the matched
pairs to estimate the association of statin use with cancer. In
the multivariable Cox regression, there was adjustment for
propensity score, as well as other covariates, to control for
any residual confounding; however, the propensity score was
nonsignificant in the final model (Online Table 2). Cova-
riates included in the Cox regression model were all vari-
ables included in the propensity model (including flags for
imputed BMI and VLDL); concomitant diagnoses (e.g.,
chronic obstructive pulmonary disease) before time zero; use
of various medications (tumor necrosis factor alpha inhibitors,
immunosuppressants, glucocorticoids, omega-3, acetylsalicylic
acid, hormones, or nonsteroidal anti-inflammatory drugs) be-
fore time zero; and metabolic measurements (LDL, VLDL,
total cholesterol, triglycerides, BMI). In addition, the def-
inition of a diagnosis of a condition before time zero was
adjusted to include persons on condition-specific medica-
tion for diabetes, hypertension, peripheral vascular disease,
and ischemic heart disease. For example, the use of sulfo-
nylureas or insulin was used as a surrogate for a diagnosis of
diabetes mellitus. Interactions were formally tested by en-
tering interaction terms between statin use and the main
predictor variables, adjusting for propensity to use statins.
Only 2 interaction terms were statistically significant: ace-
tylsalicylic acid-statins and hormones-statins. However,
these 2 interaction terms did not substantially alter the
findings; therefore, no interaction terms were included in
the final model. All data analyses were performed using SAS
version 9.1 (proc logistic for generating propensity scores,
proc lifetest for generating Kaplan-Meier curves, proc SQL
for generating plots, and proc freq, proc means, proc ttest,
and proc sort for descriptive statistics and significance
testing).
Results
Patient attrition and characteristics. As of February 2009,
the database contained information on 11,196,881 patients,
of whom 1,191,822 (10.6%) had ever used a statin. After
exclusion of patients with insufficient history, age outside
the target range, or diagnosis of cancer before time zero,
203,763 patients on medication and 159,004 patients never
on medication remained for analysis (Fig. 1). The use of
these variables for exclusion was required to eliminate
possible confounding influences and adhere to age guide-
lines. Patients taking a statin differed from those not taking
a statin for most characteristics before matching (Table 1).
Specifically, before matching, statin users were older with
higher comorbidity burden and concomitant medication use
compared with those not taking a statin. After matching, allbaseline covariates were well balanced between the 2 groups,
as shown by nearly identical frequencies in those patients
taking a statin and those not taking a statin (Table 1).
Matched patients had an average time in the database of
approximately 8 years, with 85% 5 years. The follow-up
interval after time zero for patients taking a statin was 4.7
2.2 years and 4.6  2.2 years for matched patients not
taking a statin.
Statin use and cancer. Before matching, cancer occurred
in 23,906 of the 203,763 patients taking a statin (11.7%)
and in 17,457 of the 159,004 patients (11.0%) not taking a
statin (Table 2). After the 1:1 matching, however, there
were 45,857 patients in each group, and the incidence of
cancer in patients taking a statin decreased to 11.37%
compared with 11.11% in matched patients not taking a
statin. No particular cancer type predominated (Online
Table 3).
The multivariate-matched Cox regression analysis
showed a nonsignificant hazard ratio of 1.04 (95% CI: 0.99
to 1.09) (Online Table 2). Similarly, Kaplan-Meier curves
for diagnosis of any cancer up to 10 years showed no
difference for patients taking a statin and those not taking a
statin (data not shown). Interactions of statins with clini-
cally relevant covariates were significant only for acetylsali-
cylic acid and hormones. As expected, colinearity was
apparent for LDL and total cholesterol. This did not
invalidate any results because the objective was to assess the
overall association between statin use and cancer and not to
interpret the coefficients of the covariates.
Discussion
This retrospective database analysis of a general population
of 45,857 matched pairs of patients with an average of 4.6
years of follow-up after time zero revealed no statistically
significant association of statins with cancer. Results are
consistent with the fact that a plausible biological mecha-
nism to implicate statins as causative agents in cancer has
never been demonstrated. In fact, numerous preclinical
studies have supported the potential anticancer activity of
these compounds, providing evidence of their antiprolifera-
tive, proapoptotic, anti-invasive, and radiosensitizing prop-
erties (26–28). In this analysis, the distributions of cancer
types seen in both groups were comparable. Cancer is a
multifactorial disease, and if statins were truly associated
with an increase in cancer, we would have expected to see an
increase in at least 1 type of cancer, as is typically seen with
toxin-related neoplasms.
Most importantly, there are ample clinical trial data in the
literature to refute a statin association with cancer. In 2005,
the Cholesterol Treatment Trialists published a meta-
analysis of 14 randomized trials of statins involving more
than 90,000 patients, with a pooled risk ratio for cancer after
randomization of 1.0 (95% CI: 0.95 to 1.04) (29). More
recently, Alsheikh-Ali et al. (8) reported a Bayesian meta-
analysis of 15 randomized trials of statins with more than
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an incidence rate ratio of 1.02 (95% CI: 0.95 to 1.10), and
concluded that statins have no effect on cancer risk at all
LDL levels. Furthermore, in a recent synthesis of multiple
studies using real-world data, Taylor et al. (30) reported a
meta-analysis of 20 case-control trials of more than 100,000
cancer cases and more than 3.4 million controls. They
computed an odds ratio of 0.71 (95% CI: 0.56 to 0.89) for
any cancer, suggesting a protective effect of statins. Clearly,
All 'Cleaned' patients in
February 2009 
database (DB)
N=11,196,881
All patients EVER on a 
Statin
N=1,191,822
Patients on medication with 
insufficient history in DB*
N=912,838
Patients on medication with 
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N=59,796
Patients on medication, 
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Patients with Diagnosis (Dx) 
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start date
N=15,425
Medication sample for use in 
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Users - AFTER MATCHING
N=45,857
Patients NOT Matched
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‡
Figure 1 GE Centricity Database Statin Attrition Diagram
*Patients on medications (med) must have 1 year prior to medication start date A
years of history in the database to be included in the study. ‡Males must be over
of medication.the weight of clinical evidence to date supports thesefindings showing no significant association between statin
use and incidence of cancer.
Historically, the use of observational data to help answer
clinical questions has been limited by the available datasets,
chiefly administrative claims data, which are better suited
for use and costs studies. Yet with the increasing uptake of
EMRs by healthcare providers, and their resulting databases
of large numbers of patients with clinically rich, longitudinal
data, interest is greater than ever in using these datasets to
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45 yehelp answer clinical questions. Witness the U.S. Food and
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hopes to actively query diverse automated healthcare data
holders, including EMRs, to evaluate possible medical
product safety issues quickly and securely (31). The GE
Descriptive Statistics Before and After MatchingTable 1 Descriptive Statistics Before and After Matching
On Medication
Before Matching
Never on Medi
Before Matc
Total 203,763 159,004
Sex
Female 93,777 (46.02) 77,246 (48
Male 109,986 (53.98) 81,758 (51
Age, yrs
40–49 12,973 (6.37) 16,475 (10
50–59 53,854 (26.43) 48,526 (30
60–69 66,745 (32.76) 43,477 (27
70–79 51,509 (25.28) 32,552 (20
80 18,682 (9.17) 17,974 (11
Average age, yrs 64.82 9.65 63.51 10
Smoking status
Never 97,110 (47.66) 76,105 (47
Duration of observation window, yrs
3–3.9 7,519 (3.69) 8,244 (5.1
4–4.9 16,278 (7.99) 16,677 (10
5 179,966 (88.32) 134,083 (84
Average time in database 8.56 3.22 8.04 3.1
Race
African American 6,721 (3.3) 5,799 (3.6
Asian 607 (0.3) 523 (0.3
Caucasian 63,882 (31.35) 47,618 (29
Hispanic 1,722 (0.85) 1,854 (1.1
Native American 177 (0.09) 97 (0.0
Other 130,654 (64.12) 103,113 (64
Concomitant diagnosis
Depression 76 (0.04) 39 (0.0
COPD or pneumoconiosis 7,569 (3.71) 5,298 (3.3
Psoriasis 1,423 (0.7) 1,028 (0.6
Rheumatoid arthritis 1,710 (0.84) 1,635 (1.0
Crohn’s disease 252 (0.12) 328 (0.2
Ulcerative colitis 441 (0.22) 396 (0.2
Chronic hepatitis B or C 94 (0.05) 292 (0.1
Cerebrovascular disease 9,403 (4.61) 3,726 (2.3
New definition diabetes diagnosis 49,355 (24.22) 13,981 (8.7
New definition hypertension diagnosis 120,293 (59.04) 53,820 (33
New definition peripheral vascular disease 17,067 (8.38) 3,107 (1.9
New definition ischemic heart disease 72,671 (35.66) 23,964 (15
Screenings
Pap test 3,498 (1.72) 2,579 (1.6
PSA 9,693 (4.76) 5,928 (3.7
Concomitant medications
TNF inhibitors 495 (0.24) 479 (0.3
Immunosuppressant (nonglucocorticoid) 3,618 (1.78) 2,823 (1.7
Glucoorticoids 18,374 (9.02) 13,295 (8.3
Omega-3 3,061 (1.5) 1,151 (0.7
ASA 46,615 (22.88) 21,434 (13
Hormones (estrogen  progestins) 21,608 (10.6) 17,485 (11
NSAIDs (including COX-2 inhibitors) 52,930 (25.98) 37,336 (23Centricity database used in this study is perfectly suited forsafety analyses such as these because it provides a very large,
current, and representative sample of ambulatory patients in
the United States.
Statistical methodologies for analysis of these large EMR
p Value*
Before Matching
On Medication
After Matching
Never on Medication
After Matching
p Value*
After Matching
45,857 45,857
21,904 (47.77) 21,751 (47.43) 0.32
0.001 23,953 (52.23) 24,106 (52.57)
2,936 (6.4) 4,234 (9.23)
13,134 (28.64) 13,032 (28.42)
15,509 (33.82) 12,818 (27.95)
10,759 (23.46) 10,449 (22.79)
3,519 (7.67) 5,324 (11.61)
0.001 64.2 10.44 64.19 9.45 0.89
0.22 22,531 (49.13) 22,625 (49.34) 0.54
1,955 (4.26) 2,223 (4.85)
4,335 (9.45) 4,571 (9.97)
39,567 (86.28) 39,063 (85.18)
0.001 8.43 3.43 8.43 3.23 0.96
0.001 1,903 (4.15) 1,869 (4.08) 0.58
0.10 209 (0.46) 204 (0.44) 0.84
0.001 18,252 (39.8) 18,221 (39.73) 0.84
0.001 547 (1.19) 499 (1.09) 0.14
0.01 29 (0.06) 28 (0.06) 0.99
0.001 24,917 (54.34) 25,036 (54.6) 0.43
0.04 25 (0.05) 20 (0.04) 0.55
0.001 1,801 (3.93) 1,746 (3.81) 0.36
0.06 335 (0.73) 366 (0.8) 0.26
0.001 402 (0.88) 389 (0.85) 0.67
0.001 83 (0.18) 86 (0.19) 0.88
0.04 121 (0.26) 110 (0.24) 0.51
0.001 28 (0.06) 33 (0.07) 0.61
0.001 1,683 (3.67) 1,633 (3.56) 0.39
0.001 7,407 (16.15) 7,258 (15.83) 0.18
0.001 22,030 (48.04) 22,500 (49.07) 0.002
0.001 1,741 (3.8) 1,561 (3.4) 0.002
0.001 11,355 (24.76) 11,218 (24.46) 0.30
0.03 925 (2.02) 925 (2.02) 0.99
0.001 2,409 (5.25) 2,422 (5.28) 0.86
0.001 120 (0.26) 122 (0.27) 0.95
0.99 773 (1.69) 782 (1.71) 0.84
0.001 4,267 (9.31) 4,299 (9.37) 0.73
0.001 519 (1.13) 518 (1.13) 0.99
0.001 8,910 (19.43) 8,973 (19.57) 0.61
0.001 5,693 (12.41) 5,717 (12.47) 0.82
0.001 13,016 (28.38) 12,950 (28.24) 0.63
Continued on next pagecation
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groups that are balanced with regard to important determi-
nants of exposure to the intervention of interest. Our
matching process created pairs with propensity scores
within 4 decimal places and has thus provided extremely
well-matched comparison groups. Although residual con-
founding cannot be excluded, we are fairly confident that
our cancer results are not being obscured by unmeasured
confounders.
New EMR technologies are enabling powerful statistical
evaluations of what would be considered huge databases
from the perspective of the clinical trialist. Indeed, it is from
the impressively large numbers of the GE Centricity EMR
database that the strength of the current study’s findings
emerges. Nevertheless, we recognize 3 potential limitations
of this approach.
Study limitations. First, propensity scoring methods may
not completely eliminate bias that is due to unmeasured or
hidden covariates (35). There is the possibility that the
comparison groups may differ as an artifact of the method
used to assign patients to treatment groups. Specifically,
control group patients could never be prescribed statins for
the duration of their observation interval, but statin group
patients could be assigned to the statin group on the basis of
a single statin prescription decision, regardless of their
subsequent medication adherence or duration of use. Fur-
ther, the propensity match itself results in further winnow-
ContinuedTable 1 Continued
On Medication
Before Matching
Never on Medi
Before Matc
Strata according to time zero, calendar time
Before January 1, 2000 17,148 (8.42) 16,942 (10
January 1, 2000 to December 31, 2001 26,807 (13.16) 24,147 (15
January 1, 2002 to December 31, 2003 47,629 (23.37) 36,029 (22
January 1, 2004 to December 31, 2005 72,504 (35.58) 51,015 (32
January 1, 2006 to December 31, 2007 39,675 (19.47) 30,871 (19
No. of imputations per measure
Imputed BMI 20,914 (10.26) 21,198 (13
Imputed VLDL 173,191 (85.0) 137,839 (86
BMI 30.04 5.88 28.93 5.8
LDL 132.87 36.59 118.34 32
VLDL 180.37 78.24 170.79 64
Triglycerides 179.74 120.65 147.06 10
Total cholesterol 215.49 42.39 199.37 37
No. of office visits before time zero 8.59 (13.03) 6.18 (10
Values shown are n, n (%), or mean  SD. *p values for the UNMATCHED data were done using t-t
ere used. Unmatched tests were used for comparisons before matching and matched tests wer
ASA acetylsalicylic acid; BMI body mass index; COPD chronic obstructive pulmonary disea
PSA  prostate-specific antigen; TNF  tumor necrosis factor; VLDL  very low density lipoprotei
Cancer and Statin UseTable 2 Cancer and Statin Use
On Medication
Before Matching
On
Afte
Total 203,763Cancer after time zero, n (%) 23,906 (11.73) 5,215 (11ing of the data from 159,004 potential pairs to 45,857
analyzable pairs. This stringent restriction was necessary
because any result based on the full dataset of 159,004 pairs
could easily be attributed to confounding. We imputed
values for 2 variables (BMI and VLDL) before time zero to
increase the sample size available for the match; however,
we adopted a conservative approach by including flags for
these in our Cox regression.
Second, in fitting the model for propensity matching, we
were forced to omit data for records missing those variables.
We used variables for elimination that were clearly associ-
ated with confounding (age outside the target range, insuf-
ficient history, or pre-existing diagnosis of cancer). Al-
though this requirement resulted in substantial winnowing
of the data (retention of 17.1% of patients on medication
and 1.6% of patients never on medication), this restriction
of data is necessary to control for confounding in observa-
tional data. Recognizing that the requirement for complete
data may create some bias in the results, the distribution of
known variables for the group taking a statin and the group
not taking a statin were analyzed and found to be similar.
Third, these results may not be generalizable to the
overall population of U.S. adults taking statins. Although
the population of adults in the GE database is representative
of the U.S. population, the representativeness of the
matched cohorts is restricted due to the database winnowing
inherent in the analysis. The results of the analysis may be
p Value*
Before Matching
On Medication
After Matching
Never on Medication
After Matching
p Value*
After Matching
0.001 4,590 (10.01) 5,073 (11.06) 0.001
0.001 7,435 (16.21) 7,399 (16.13) 0.75
0.001 9,568 (20.86) 8,452 (18.43) 0.001
0.001 15,159 (33.06) 15,101 (32.93) 0.69
0.68 9,105 (19.86) 9,832 (21.44) 0.001
0.001 4,519 (9.85) 4,497 (9.81) 0.82
0.001 38,102 (83.09) 38,055 (82.99) 0.69
0.001 29.56 5.56 29.61 6.16 0.21
0.001 125.85 35.35 126.18 33.0 0.13
0.001 173.22 73.23 172.15 77.67 0.03
0.001 207.81 40.01 207.98 37.44 0.53
0.001 161.86 89.1 160.56 106.14 0.05
0.001 8.56 (10.79) 8.37 (13.11) 0.02
independent samples or chi-square, but for the MATCHED data paired t-tests and McNemar tests
for comparisons after matching.
X cyclooxygenase; LDL low-density lipoprotein; NSAID nonsteroidal anti-inflammatory drug;
ation
ching
Never on Medication
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Never on Medication
After Matching
7 159,004 45,857cation
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.66)
.19)
.66)
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.42)
.33)
.69)
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.05
.53
2.83
.22
.71)
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45,85.37) 17,457 (11.00) 5,094 (11.11)
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who match the characteristics of our study groups.
On the basis of these findings, further exploratory anal-
yses of this and other EMR databases are recommended to
assess whether our findings might differ by type of statin
because not all statins are the same in terms of chemical
properties and potency. In addition, combination products,
particularly with ezetimibe, should be assessed. Adherence
to statins in relation to any cancer associations would also be
of interest and could perhaps be assessed by modifying
techniques initially developed for application to claims
datasets (36). Duration of statin use could also be assessed in
this context. Last, it would be of interest to use the GE
Centricity database to further investigate LDL levels and
cancer risk, especially because the treatment targets for
serum lipids are set even lower (37) to levels (e.g., LDL
100 mg/dl) that have been implicated in previous cancer
association studies (18,38–40).
Conclusions
This EMR database analysis of more than 91,000 U.S.
adults with complete clinical datasets who were propensity
matched with an average of 4.6 years of follow-up, demon-
strated no statistically significant increased risk of cancer
associated with statins.
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